Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019)
Black Diamond Therapeutics' (BDTX) quarterly Preferred Stock Liabilities came in at $200.6 million in Q4 2019, up 230.05% YoY from $60.8 million in Q4 2018, and up 73.15% on a QoQ basis from $115.8 million in Q3 2019.
Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 2 years of Preferred Stock Liabilities data on file, last reported at $200.6 million in Q4 2019.
- Quarterly Preferred Stock Liabilities rose 230.05% year-over-year to $200.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $200.6 million (up 230.05% YoY) and the FY2019 annual result came in at $200.6 million, up 230.05% from the prior year.
- Preferred Stock Liabilities rose to $200.6 million in Q4 2019, from $115.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $200.6 million in Q4 2019 to a low of $60.8 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 200.57 Mn |
| Sep 30, 2019 | 115.84 Mn |
| Jun 30, 2019 | 60.77 Mn |
| Mar 31, 2019 | 60.77 Mn |
| Dec 31, 2018 | 60.77 Mn |